Accepted 12 April 2006 Published online 13 November 2006 in Wiley InterScience ( DOI: /hed.
|
|
- Milton Williams
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE PHASE II ANALYSIS OF PACLITAXEL AND CAPECITABINE IN THE TREATMENT OF RECURRENT OR DISSEMINATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK REGION Jens D Bentzen, MD, 1 Hanne Sand Hansen, MD 2 1 Department of Radiotherapy and Oncology, University Hospital in Herlev, 2730, Herlev, Denmark. jeben@herlevhosp.kbhamt.dk 2 Department of Oncology, Finsencenter, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark Accepted 12 April 2006 Published online 13 November 2006 in Wiley InterScience ( DOI: /hed Abstract: Background. The aim of this phase II study was to evaluate the antitumor activity and toxicity of a non-platin containing regimen with paclitaxel and capecitabine. Methods. Fifty patients with recurrent or disseminated squamous cell carcinoma were included in the study. The treatment consisted of paclitaxel 175 mg/m 2 once every third week and capecitabine 825 mg/m 2 per oral (p.o.) twice daily (bid) for 2 weeks. Results. The overall response rate according to the World Health Organization (WHO) criteria was 42%. Two patients had a complete response (CR), 19 patients had a partial response (PR), 14 patients had no change (NC), 12 patients had progressive disease (PD), and 3 patients were not evaluable (NE). The median survival time was 8 months. Toxicity was very moderate. Only 10% of 315 delivered treatments had to be given in reduced dose or postponed for a week or more. Conclusions. The toxicity was low and manageable. The overall response rate was comparable to the commonly used cisplatin/5-fluorouracil regimen. VC 2006 Wiley Periodicals, Inc. Head Neck 29: 47 51, 2007 Keywords: paclitaxel; capecitabine; head and neck cancer; squamous cell carcinoma; toxicity Correspondence to: J. D. Bentzen VC 2006 Wiley Periodicals, Inc. The incidence of head and neck cancer in Denmark approaches 1000 patients per year. The primary treatment strategy is accelerated radiotherapy (66 68 Gy/2Gy/fraction, 6 fractions/week) in combination with the hypoxic radiosensitizer nimorazol. Surgery is selected for some of the oral cancers and for salvage treatment. Chemotherapy is mainly used for patients with recurrent or primarily disseminated disease, when local treatment with curative intent is no longer possible. No standard chemotherapy regimen has yet been agreed upon either in Denmark or in the rest of the world. Most regimens tested so far contain cisplatin, a drug that in Denmark often requires hospitalization because of our rather long-lasting prehydration and posthydration regimens, and which has considerable toxicity, especially in this patient population. Cisplatin combined with 5-fluorouracil (5-FU) is probably the most used combination regimen, yielding response rates of about 33%. 1 The aim of this study was to try to find a regimen offering a more favorable toxicity profile com- Paclitaxel and Capecitabine in HNSCC HEAD & NECK DOI /hed January
2 bined with a comparable or improved response rate in comparison to the cisplatin-containing regimens. Paclitaxel (Taxol, Bristol-Myers Squibb, Bromma, Sweden) is an interesting antimitotic drug that is already frequently used in the treatment of several other cancers such as ovarian cancer and breast cancer. The experience with paclitaxel in head and neck cancer is limited, with reported response rates in different combination regimens ranging from 23% to 78%. 2 5 Doses of 135 to 175 mg/m 2 can be given safely as 3-hour infusions every 3 weeks on an outpatient basis. Capecitabine (Xeloda, Roche, Basel, Switzerland) is an oral prodrug to 5-FU. Its activation to 5-FU by thymidine phosphorylase occurs mainly within the tumors. 6 A combination regimen with paclitaxel 175 mg/m 2 every third week and capecitabine 825 mg/m 2 twice daily (bid) days 1 to 14, followed by 1-week rest, has previously been found to be safe in a breast cancer study. 7 MATERIALS AND METHODS Patient Eligibility. Patients were eligible under the following conditions: (1) histologically confirmed recurrent or disseminated squamous cell carcinoma of the head and neck region, not suitable for curative radiotherapy or salvage surgery; (2) measurable disease in minimum 2 dimensions; (3) age 18 to 75 with World Health Organization (WHO) performance status 2; (4) no previous chemotherapy for 1 month; (5) no other severe life-shortening disease or other malignant disease; and (6) adequate bone, liver, and renal function. Patients had to be mentally well and psychologically capable of understanding and adhering to the treatment plan. The protocol was approved by the Ethics Committees of Copenhagen, Denmark. All patients gave written informed consent. Treatment. The treatment plan was as follows: Day 1: Paclitaxel 175 mg/m 2 i.v. over 3 hours. Days 1 to 14: Capecitabine 825 mg/m 2 per dose orally bid (twice daily) for 2 weeks, with 200 ml water taken <30 minutes after a meal. After a 1-week interval without medication, the treatment was repeated. The patients received the following intravenous (i.v.) premedication 30 minutes before administration of paclitaxel: dexamethasone 10 mg, clemastine 2 mg, and nizatidine 100 mg. Statistical Analysis. The criteria for response were based on the WHO definition. 8 Survival curves were generated according to the Kaplan Meier method. 9 Survival was calculated from the start of chemotherapy until death. Surviving patients were censored at the day of their last follow-up visit. Time to progression was calculated from the first day of chemotherapy to the first documentation of progression. RESULTS Table 1. Patient characteristics. Characteristics No. of patients % Total no. of patients Sex Male Female 8 16 Age, y 54.7 (range, 32 73) WHO performance Primary disease site Nasopharynx 9 18 Oropharynx 8 16 Hypopharynx 7 14 Larynx 7 14 Oral cavity Nasal cavity or maxillary sinus 1 2 Other 3 6 Prior therapy None 3 6 Radiotherapy and surgery Radiotherapy alone Surgery alone 1 2 Disease site at study entry Local only Regional only 6 12 Distant metastasis only 6 12 Locoregional Local and distant metastaseis 3 6 Regional and distant metastaseis 1 2 Local, regional, and distant 6 12 Abbreviation: WHO, World Health Organization. Patient Characteristics. Fifty patients were consecutively included in the study between January 2001 and April The patient characteristics are listed in Table 1. The distribution according to the International Union Internationale Contre le Cancer (UICC 1997) TNM classification 10 at the time of the primary diagnosis and at the begin- 48 Paclitaxel and Capecitabine in HNSCC HEAD & NECK DOI /hed January 2007
3 Table 2. UICC TN classification. Initial status N0 N1 N2 N3 Total T T T T T Total Status at time of entrance in study rn0 rn1 rn2 rn3 Total rt rt rt rt rt Total Abbreviations: UICC, Union Internationale Contre le Cancer; TN, tumor node. ning of chemotherapy is shown in Table 2. Twenty-nine of the patients had been treated with radiotherapy as the primary treatment, 2 in combination with operation. Eighteen patients had had primary surgery, 17 of whom had undergone additional postoperative radiation. The 3 patients with primarily disseminated disease had not had any other treatment before the study chemotherapy. Three of the 50 patients had primary distant metastases, all in the lung. Thirty-eight patients had local tumor recurrence or remnant local tumor. Twenty-three patients had regional lymph node metastases. More than one half of the lymph nodes were localized in region 2: 38% in region 3 and 10% in region 4. A total of 42 (84%) ofthe patients had tumor recurrence within the radiation fields. Distant metastases were seen in 16 patients. Ten patients had lung metastasis, 5 had liver metastasis, and 4 had bone metastasis. Five patients had metastasis to >1 distant site; 29 patients started chemotherapy for their first relapse, 11 patients for the second relapse, and 7 patients after 3 to 6 relapses. Response and Survival. Treatment was well tolerated when given on an outpatient basis. A total of 50 patients received 315 series of chemotherapy, 20 patients had >6 series, and 6 patients had >12 series. The response rate according to the WHO criteria was 42% (see Table 3). Two patients had a complete response (CR), and 19 patients had a partial response (PR). Fourteen patients were evaluated as having no change (NC), and 12 patients had progressive disease (PD). Three patients died before they received 3 series and were therefore not eligible for response evaluation (NE), but they where included in the response evaluation (intention to treat analysis). The mean time to progression (TTP) was days (5.2 months). A Kaplan Meier plot of crude survival is shown in Figure 1. The median survival time was 244 days or 8 months. The 2 patients who had CR are still alive with no evidence of disease (NED). Toxicity. The worst registered toxicities are listed in Table 4. Thirteen series of 315 (10%) were administered in reduced dose or postponed for 1 week. One patient did not complete the first cycle. Hair loss and hand-and-foot syndrome were the most common side effects. Only 1 patient experienced grade 4 gastrointestinal toxicity. Hemato- Table 3. Best response: WHO, intention to treat analysis*. Response No. of patients % CR 2 4 PR NC PD NE 3 6 Total Abbreviations: WHO, World Health Organization; CR, complete response; PR, partial response; NC, no change; PD, progressive disease; NE, not evaluable. *Mean time to progression (TTP) in 44 patients was 157 days (5.2 months). FIGURE 1. Kaplan Meier plot of crude survival for the 50 patients. Median survival time, 244 days. Paclitaxel and Capecitabine in HNSCC HEAD & NECK DOI /hed January
4 Table 4. Toxicity observed in 50 patients: WHO criteria. No. of patients (%) by grade Grade 0 Grades 1 2 Grades 3 4 Not evaluated Skin (hand-and-foot syndrome) 20 (40) 20 (40) 6 (12) 4 (8) Alopecia* 2 (4) 24 (grade 1) (48) 19 (grade 2) (38) 5 (10) Allergy 36 (72) 3 (6) 1 (2) 10 (20) Mucositis 31 (62) 11 (22) 3 (6) 5 (10) Nausea 15 (30) 29 (58) 2 (4) 4 (8) Vomiting 29 (58) 15 (30) 2 (4) 4 (8) Diarrhea 17 (34) 26 (52) 3 (6) 4 (6) Infection 17 (34) 22 (44) 8 (16) 3 (6) Neurotoxicity 23 (46) 20 (40) 1 (2) 6 (12) Arthritis/muscle pain 14 (28) 31 (62) 0 (0) 5 (10) Cardiac 32 (62) 2 (4) 0 (0) 16 (32) Urogenital 28 (56) 7 (14) 1 (2) 14 (28) Anemia 15 (30) 32 (64) 0 (0) 3 (6) Leukocytopenia 22 (44) 18 (36) 7 (14) 3 (6) Neutropenia 24 (48) 13 (26) 9 (18) 4 (8) Thrombocytopenia 40 (80) 7 (14) 0 (0) 3 (6) Abbreviation: WHO, World Health Organization. *For alopecia, grade 1 is partial hair loss; grade 2 total hair loss. There is no grade 3 or 4. logic toxicity (neutropenia) was moderate, with only 9 patients experiencing grade 3 and none grade 4 toxicity. There were no toxic deaths. DISCUSSION Studies of combination therapy with paclitaxel and capecitabine for recurrent or metastatic head and neck cancer has not been published before. The combination of taxanes and capecitabine has been used for metastatic mammary cancer and for colorectal cancer. A study by McDonald and Miles 11 has shown a synergistic effect in recurrent mammary cancer of paclitaxel and capecitabine. For metastatic colorectal cancer, a randomized study with paclitaxel and capecitabine versus the Mayo Clinic regimen (5-FU and leucovorin) showed at least equal results. Median time to progression was 140 versus 144 days, and median survival time was 392 versus 391 days. The response showed 27% versus 54% in favor of the paclitaxel and capecitabine regimen. 12 Single agents such as methotrexate, cisplatin, 5-FU, paclitaxel, bleomycin, and ifosfamid are effective with responses ranging from 15% to 33% and 5- to 6-month median survival times in pretreated patients. 13 The most used combination, cisplatin and 5-FU, gives overall response rates on the order of 30% and median survival times of 4 to 6 months. 14,15 The side effects associated with this regimen are considerable, however. In a recent randomized phase III study by the Eastern Cooperative Oncology Group (ECOG), cisplatin (100 mg/m 2 day 1) plus 5-FU (1000 mg/m 2 /24 hours, days 1 to 4) (CF) was compared with cisplatin (75 mg/m 2 day 1) and paclitaxel (175 mg/m 2 day 1) (CP). 5 The estimated median survival times were not significantly different (CF 8.7 months and CP 8.1 months). Response rates were 27% (CF) and 26% (CP). Toxicities were similar between the groups and consisted mainly of myelosuppression, nausea, and stomatitis. Neutropenia was common, with grade 3 and 4 neutropenia in 67% (CF) and 55% (CP). In the present study, we had a very low toxicity, with only 10% of the planned treatments having to be given in a reduced dose and especially a very low frequency of grades 3 and 4 neutropenia. Hand-and-foot syndrome was also a minor problem, probably because the dose in our study was a slightly lower than the dose of capecitabine used in most colorectal trials. The overall response rate in this study was 42% (intention to treat analysis), which is definitely comparable to the cisplatin 5-FU regimen. The mean TTP was 5.2 months and the median overall survival time (Kaplan Meier) was 244 days or 8 months, which is also comparable to the best studies reported so far, including the recent ECOG study. 5 The tested regimen with the combination of capecitabine 825 mg/m 2 bid days 1 to 14 and paclitaxel 175 mg/m 2 day 1 every third week was well tolerated on an outpatient basis and was associated with a very modest toxicity. The combination regimen provides reasonable response rates in comparison with the cisplatin 5-FU regimen. In 50 Paclitaxel and Capecitabine in HNSCC HEAD & NECK DOI /hed January 2007
5 addition, this regimen can easily be administered on an outpatient basis. In our view, this regimen could be a good substitute for the currently applied cisplatin 5-FU regimen. Because of the promising preliminary results, the study is currently being extended to accrue a total of 150 patients to provide a more robust estimate of response rates and survival. REFERENCES 1. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A metaanalysis of randomized trials. J Clin Oncol 1996;14: Hitt R, Paz-Ares L, Hidalgo M, et al. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin Oncol 1997;24(suppl 19): Gebbia V, Testa A, Cannata G, Gebbia N. Single agent in advanced squamous cell head and neck carcinoma. Eur J Cancer 1996;32A: Licitra L, Fulfaro F, Grandi C, et al. Phase II study of biweekly/cisplatin. Proc Am Soc Clin Oncol 1996; Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23: Miwa M, Lira M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34: Villalona-Calero MA, Blum JL, Jones SE, et al. A phase I and pharmacologic study of and in breast cancer patients. Ann Oncol 2001;12: Miller AB, Hoogstraten B, Staquet M, Winkler A. reporting results of cancer treatment. Cancer 1981;47: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: Wittekind C, Wagner G, editors. UICC: TNM Klassifikation maligner Tumoren. 5th ed. Berlin: Springer; McDonald F, Miles D. Xeloda and Taxotere: a review of the development of the combination for use in metastatic breast cancer. Int J Clin Pract 2003;57: Van Cutsem EV, Twelves C, Cassidy J, et al. Oral compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;9: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia, PA: Lippincott-Raven; p Jacobs C, Lynman V, Velez-Garcia E, et al. A phase III randomized comparison of cisplatin plus fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin and carboplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: Paclitaxel and Capecitabine in HNSCC HEAD & NECK DOI /hed January
Vision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More informationORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER
ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4
More informationIrinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination
Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c
More informationAccepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179
ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationORIGINAL ARTICLE. Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation
ORIGINAL ARTICLE Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation Michael E. Poole, PA-C, MPH; Scott L. Sailer, MD; Julian G. Rosenman,
More informationGemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment
DOI: 10.18056/seci2014.6 Gemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment Zedan A 1, Soliman M 2, Sedik MF 1 1 Medical Oncology Department,
More informationANTICANCER RESEARCH 25: (2005)
Carboplatin in Combination with Raltitrexed in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Multicentre Phase II Study of the Gruppo Oncologico Dell Italia Meridionale (G.O.I.M.) DOMENICO
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationSingle Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
ORIGINAL RESEARCH Single Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN) 1 Gilbert J, 1 Dang T, 2 Cmelak A, 3 Shyr Y, 4 Netterville J, 4 Burkey
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationCetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationAccepted 24 October 2007 Published online 22 January 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.
ORIGINAL ARTICLE PHASE II STUDY OF GEFITINIB FOR THE TREATMENT OF RECURRENT AND METASTATIC NASOPHARYNGEAL CARCINOMA Daniel T. T. Chua, MD, 1 William I. Wei, MD, 2 Maria P. Wong, MD, 3 Jonathan S. T. Sham,
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationWeekly Paclitaxel for Metastatic Breast Cancer in Patients Previously Exposed to Paclitaxel
www.journalofcancerology.com PERMANYER J Cancerol. 0;:-9 JOURNAL OF CANCEROLOGY CLINICAL CASE Weekly Paclitaxel for Metastatic Breast Cancer in Patients Previously Exposed to Paclitaxel Benjamín Dávalos-Félix,
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationConcurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
Original article Annals of Oncology 14: 1306 1311, 2003 DOI: 10.1093/annonc/mdg330 Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary A. Argiris
More informationFluorouracil/Leucovorin/Interferon α-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
Chapter 8 Fluorouracil/Leucovorin/Interferon α-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Jan Buter, Harm A.M. Sinnige, Dirk Th. Sleijfer, Elisabeth
More informationORIGINAL ARTICLE. Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx
ORIGINAL ARTICLE Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx Sandro J. Stoeckli, MD; Andreas B. Pawlik, MD; Margareta Lipp, MD; Alexander Huber, MD;
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationThe management of advanced supraglottic and
ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1
More informationThe Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer
The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer JOANNE L. BLUM U.S. Oncology and Baylor-Charles A. Sammons Cancer Center, Dallas,
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationBCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
More informationA PILOT STUDY OF FIRST-LINE CHEMOTHERAPY WITH 5-FU AND PLATINUM IN ADVANCED AND RECURRENT CANCER OF THE CERVIX
A PILOT STUDY OF FIRST-LINE CHEMOTHERAPY WITH 5-FU AND PLATINUM IN ADVANCED AND RECURRENT CANCER OF THE CERVIX F. Ghaemmaghami 1, N. Behtash 1, F. Yarandi 1, A. Moosavi 1, Gh.R. Toogeh 2 and N. Khanafshar
More informationLow Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline
Low Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline Rabab Mahmoud and Omnia Abd-elfattah Clinical Oncology Department,
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:
Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationPhase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
Original article Annals of Oncology 13: 1862 1867, 2002 DOI: 10.1093/annonc/mdf308 Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer V.
More informationTOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER
ORIGINAL ARTICLE TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER Dirk Rades, MD, 1 Fabian Fehlauer, MD, 2 Mashid Sheikh-Sarraf,
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPaclitaxel, Carboplatin, and Gemcitabine in the Treatment of Patients with Advanced Transitional Cell Carcinoma of the Urothelium
2298 Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Patients with Advanced Transitional Cell Carcinoma of the Urothelium A Phase II Trial of the Minnie Pearl Cancer Research Network John
More informationx Principal Investigator: Muh-Hwa Yang x IRB Approved: Yes
Clinical Trial Results Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study SAN-CHI CHEN, a,b,c PETER
More informationBCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine
BCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAVCAP Breast Dr. Susan Ellard ELIGIBILITY: First line treatment of metastatic
More informationIrinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer
Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal
More informationThe effect of induction chemotherapy followed by chemoradiotherapy in advanced head and neck cancer: a prospective study
International Journal of Research in Medical Sciences Nikam BM et al. Int J Res Med Sci. 2014 May;2(2):476-480 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: 10.5455/2320-6012.ijrms20140519
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationOutpatient Chemotherapy with S-1 for Recurrent Head and Neck Cancer
Outpatient Chemotherapy with S-1 for Recurrent Head and Neck Cancer TAKU YAMASHITA 1,2, SEIICHI SHINDEN 2, TAKAHISA WATABE 2 and AKIHIRO SHIOTANI 1 1 Department of Otolaryngology-Head and Neck Surgery,
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationConventionally, the role of chemotherapy in
THE ROLE OF CHEMOTHERAPY AND OTHER MODALITIES IN HEAD AND NECK CANCER * Patrick J. Medina, PharmD, BCOP ABSTRACT For patients with head and neck cancer (HNCA), therapy for earlier-stage disease has traditionally
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317
Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationCombined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement.
Combined chemotherapy and Radiotherapy for Patients with Breast Cancer and Extensive Nodal Involvement. Ung O, Langlands A, Barraclough B, Boyages J. J Clin Oncology 13(2) : 435-443, Feb 1995 STUDY DESIGN
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationPost-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2006 Post-Operative Concurrent Chemoradiation with Mitomycin-C for
More informationIntegrating Oxaliplatin into the Management of Colorectal Cancer
Integrating Oxaliplatin into the Management of Colorectal Cancer HANS-JOACHIM SCHMOLL, a JIM CASSIDY b a Martin-Luther-University Halle-Wittenberg, Halle, Germany; b University of Aberdeen, Aberdeen, UK
More informationGemcitabine and Capecitabine for Advanced Adenocarcinoma of the Pancreas
Gemcitabine and Capecitabine for Advanced Adenocarcinoma of the Pancreas Robert D. Levin, MD Abstract Background: Chemotherapy for advanced adenocarcinoma of the pancreas may have severe toxicities including
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationLocoregional recurrences are the most frequent
ORIGINAL ARTICLE SECOND SALVAGE SURGERY FOR RE-RECURRENT ORAL CAVITY AND OROPHARYNX CARCINOMA Ivan Marcelo Gonçalves Agra, MD, PhD, 1 João Gonçalves Filho, MD, PhD, 2 Everton Pontes Martins, MD, PhD, 2
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationNCCP Chemotherapy Regimen
Modified Roswell Park (Fluorouracil 500mg/m 2 and Folinic Acid 50mg weekly x 6) Regimen INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00427a Adjuvant
More informationSMALL-CELL LUNG cancer (SCLC) represents 20% to
Cisplatin, Etoposide, and Paclitaxel in the Treatment of With Extensive Small-Cell Lung Carcinoma By Bonnie S. Glisson, Jonathan M. Kurie, Roman Perez-Soler, Nikolous J. Fox, William K. Murphy, Frank V.
More informationTopotecan: An Oncologist s View
Topotecan: An Oncologist s View JEAN-FRANÇOIS HÉRON Centre François Baclesse, Centre Régional de Lutte Contre le Cancer, Caen, France Key Words. Topotecan Clinical trials Ovarian neoplasms Small cell lung
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationPaclitaxel in Breast Cancer
Paclitaxel in Breast Cancer EDITH A. PEREZ Mayo Foundation and Mayo Clinic Jacksonville, Jacksonville, Florida, USA Key Words. Paclitaxel Antineoplastic agents Breast neoplasms Clinical trials ABSTRACT
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 34 DECEMBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy
More informationComparison of acute toxicities and response of standard chemo radiation versus hyper fractionated radiotherapy in head and neck cancers
Original Research Article Comparison of acute toxicities and response of standard chemo radiation versus hyper fractionated radiotherapy in head and neck cancers Kuppa Prakash 1*, A. Ravi Chandran 2, M.
More informationAdverse side effects associated to metronomic chemotherapy
Adverse side effects associated to metronomic chemotherapy Elisabetta Munzone, MD Division of Medical Senology Istituto Europeo di Oncologia Milano, Italy LDM: the optimal biological dose Although there
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationPhase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
Original Article Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma Werner Scheithauer 1, Gabriela Kornek 1, Gerald Prager 1, Nadja Stranzl 1, Friedrich
More informationEFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA
ORIGINAL ARTICLE EFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA Raymond King Yin Tsang, FRCSEd, Joseph Chun Kit Chung, MRCSEd, Yiu Wing
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 22 NOVEMBER 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Adjuvant Chemotherapy for Resected Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction, and Cardia:
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationINNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB
INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB Elena Massa CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA DEGLI STUDI DI CAGLIARI ErbB Inhibition
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationStudy Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationThe TNM tumor classification system has been
ORIGINAL ARTICLE USEFULNESS OF MRI VOLUMETRIC EVALUATION IN PATIENTS WITH SQUAMOUS CELL CANCER OF THE HEAD AND NECK TREATED WITH NEOADJUVANT CHEMOTHERAPY Mehran Baghi, MD, 1 Martin G. Mack, MD, PhD, 2
More informationThe American Cancer Society estimates that 28,900 new cases of
2224 Phase II Study of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Squamous Cell Carcinoma of the Upper Respiratory or Alimentary Passages of the Head and Neck Scott H. Okuno,
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationTitle. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information
Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal
More informationINAS I. ABDELHALIM, M.D.; NAWAL M. ELSAID, M.D.; ELSAID M. ALI, M.D. and BASHEER S. ATA, M.Sc.
Med. J. Cairo Univ., Vol. 81, No. 1, December: 887-893, 2013 www.medicaljournalofcairouniversity.net Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin and 5-Flurouracil Followed by Concomitent Chemoradiotherapy
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationNCCP Chemotherapy Regimen
QUASAR (Modified) Fluorouracil (370mg/m 2 ) and Folinic Acid (50mg) Weekly INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00428a Adjuvant treatment of
More information